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ABSTRACT
Metal ions are required for many critical functions in living systems.
Scarcity of some metal ions can lead to disease. A characteristic of
metals is that they easily lose electrons from the familiar elemental or
metallic state to form positively charged ions which tend to be soluble
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absence of Zn, Ca and Cu metal ions these energies are increases.

Metal plays a critical role in function of these proteins. Our results suggested that metal plays
a particular role in the binding of the inhibitor with protein as well as structural stability and
catalysis.
KEYWORDS: Farnesyltransferase; Metlloproteins; AutoDock; Neuraminidase;Thioredoxin;
Metal ions.
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1. INTRODUCTION
The importance of metal ions in biological system is increasingly drawing attention as
indicated by the recent emergence of terms such as metallic and metallic. Approximately one
third of all of structurally-determined proteins are metal-bound,[1] and large percentages of
metals present in the human body are bound to proteins.[2, 3] This emphasizes the crucial role
of metal ions in stabilizing protein structure.[4] Most of metlloproteins play a key role in
biological process, and therefore have been considered to be a promising target for drug
discovery. The metal ion in the active site can participate in the enzymatic reaction as a
receptor for the lone pair electrons, which has an effect of weakening the chemical bonds in
the substrate. Due to such an essential role in enzymatic reaction, a chemical group that can
bind to the central metal ion is necessary in the molecular structure of a small-molecule
inhibitor that can regulate the activity of metalloproteins. This has made it much more
difficult to design an inhibitor of a metalloprotein than that of a protein without a metal
cofactor. Despite such a difficulty, a number of chemical groups that chelate and inactivate a
metal ion at the active site of metalloproteins have been reported, including carboxylate,
passport, hydroxamate, -keto acid, and diol moieties.
Metal ions are required for many critical functions in living systems. Scarcity of some metal
ions can lead to disease. A characteristic of metals is that they easily lose electrons from the
familiar elemental or metallic state to form positively charged ions which tend to be soluble
in biological fluids. It is in this cationic form that metals play their role in biology whereas
metal ions are electron deficient, most biological molecules such as proteins and DNA are
electron rich. The attraction of these opposing charges leads to a general tendency for metal
ions bind to and interact with biological molecules.[5] Well-known examples include
pernicious anemia resulting from iron deficiency, growth retardation arising from insufficient
dietary zinc, and heart disease in infants owing to copper deficiency. The ability to recognize,
to understand at the molecular level, and to treat diseases caused by inadequate metal-ion
function constitutes an important aspect of medicinal bioinorganic chemistry.
Metals perform a wide variety of tasks such as carrying oxygen throughout the body and
shuttling electrons. Haemoglobin, an iron-containing protein that binds to oxygen through its
iron atom, carries this vital molecule to body tissues. Metal ions such as zinc provide the
structural framework for the zinc fingers that regulate the function of genes in the nuclei of
cells. Similarly, calcium-containing minerals are the basis of bones, the structural framework
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of the human body. Zinc is a natural component of insulin, a substance crucial to the
regulation of sugar metabolism. Metals such as copper, zinc, iron and manganese are
incorporated into catalytic proteins the metalloenzymes-which facilitate a multitude of
chemical reactions needed for life.[5]
In addition to the metalloantibiotics, a number of drugs and potential pharmaceutical agents
also contain metal-binding or metal-recognition sites, which can bind or interact with metal
ions and potentially influence their bioactivities and might also cause damages on their target
biomolecules. For instance: Anti-inflamatory drugs, such as aspirin and its metabolite
salicylglycine, ibuprofen, the indole derivative indomethacin, bioflavonoid rutin, diclofenac,
suprofen are known to bind metal ions and affect their antioxidant and anti-inflammatory
activities.
Farnesyltransferase (FTase) is a zinc metalloenzyme that catalyzes the addition of isoprenoid
farnesyl, from farnesyl diphosphate (FPP), to a cysteine residue of a protein substrate
containing a C-terminal, CAAX motif, in which C is the cysteine that is farnesylated, A is an
aliphatic amino acid, and X is the carboxyl terminal residue.[6] Fates play crucial roles in cell
growth regulation, signal transduction and proliferation. It has been recognized as a potential
target for anticancer therapeutics.
The Swine flu is an infectious disease of swine and human, caused by influenza A virus
subtype H1N1.[7] The World Health Organization figures show that worldwide more than 214
countries have reported laboratory confirmed cases of H1N1, including over 18449 deaths
(WHO, 2010). Swine influenza A virus belong to the viral family of Orthomyxoviridae. They
are RNA viruses with a segmented genome that is comprised of eight negative-sense, singlestranded RNA segments. These eight segments encode eleven proteins in which two are
surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA). Hemagglutinin has 16
subtypes (H1, H2, H3, . . ., H16) and neuraminidase has 9 subtypes (N1, N2, N3, . . ., N9)
and this novel virus consists of subtype H1 and N1.[8, 9] NA is responsible for cleaving the
terminal sialic acid moieties from the receptors to facilitate the illusion of the progeny virions
from the infected cell. The cleavage will facilitate the virus to release and form sites of
infection in the respiratory tract. Because of its essential role in influenza virus replication
and its highly conserved active sites, NA has become the main target for drug design against
influenza virus.
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Thioredoxin (TRX), a small redox-active multifunctional protein, acts as a potent antioxidant
and a redox regulator in signal transduction. TRX expression is elevated in various types of
human cancer.
2. MATERIALS AND METHODS
Role of zinc, calcium and copper ions in the function of drug targeted proteins such as
Farnesyltransferase, Neuraminidase and Thioredoxin, respectively are analyzing using
molecular docking.
2.1 Receptor x-ray structures
The Protein Data Bank (PDB) is a repository for the 3D structural data of large biological
molecules, such as proteins and nucleic acids. The data typically obtained by X-ray
crystallography or NMR spectroscopy can be accessed at http://www.rcsb.org. The 3D
coordinates of Farnesyletransferase, Neuraminidase and Thioredoxin structure with bound
ligands were retrieved from PDB database with codes 1X81, 3B7E and 2TRX, respectively
and taken as the receptor model in flexible docking program.
Before docking all heteroatoms and water molecules were removed from .pdb file of protein
structure by charge method AMI-BCC using chimera. After removing the water molecule,
hydrogen atom was added to protein for correct ionization and tautomeric states of amino
acid residues such as Asp, Ser, Glu, Arg and His.
2.2 Active site analysis
The active site residues of Farnesyletransferase, Neuraminidase and Thioredoxin were taken
from the PDBSUM entries of 1X81, 3B7E and 2TRX. The binding site residue in
Farnesyletransferase is ASP359, LEU96, TYR361, TRP106 and TRP102. Neuraminidase has
TRY178,GLU227,ASP151,GLU119,ARG371,ILE222,ARG152,GLU277,TRY406,ARG118,
ARG292,ASN294,GLU276,SER276 and ASN294 residues. And Thioredoxin has binding
site residues LEU94, ALA93, ILE38 and MET37.
2.3 Inhibitors Dataset
The information regarding the experimentally known inhibitors of Farnesyltransferase protein
such as Azacitidine, Gemcitabine, Tipifarnib and Toremifene and for Thioredoxin such as
Granisetron and Nilutamide was obtained from the Drugbank database. The anti-flu drugs
oseltamivir and zanamivir against Neuraminidase were obtained from the literature.[11] The
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3D structures of known inhibitors were downloaded from the PubChem compound database.
List of experimentally known inhibitors is shown in Table 1.
2.4 Molecular docking
Docking of known inhibitors screened from literature against Farnesyltransferase,
Neuraminidase and Thioredoxin structures were done using molecular docking program
AutoDock 3.0.5. Gasteiger charges are added to the ligand and maximum 6 numbers of active
torsions are given to the lead compounds using AutoDock tool.[10] Kollman charges and the
solvation term were then added to the protein structure using the same. We have made the
grid and adjusted the number of points in X, Y, Z-axis so that the entire active site of the
proteins is covered. The default value is 0.375 Å between grid points, which is about a
quarter of the length of a carbon-carbon single bond. The spacing between grid points can be
adjusted with another thumbwheel. Grid spacing values of up to 1.0 Å can be used when a
large volume is to be investigated. The Lamarckian genetic algorithm implemented in
Autodock was used. Docking parameters were as follows: 30 docking trials, population size
of 150, maximum number of energy evaluation ranges of 25,0000, maximum number of
generations is 27,000, mutation rate of 0.02, crossover rate of 0.8, Other docking parameters
were set to the software’s default values. After docking, the ligands were ranked according to
their docked energy as implemented in the AutoDock program.
3. RESULTS AND DISCUSSION
The medicinal uses and applications of metals and metal complexes are of increasing clinical
and commercial importance. The constituents of proteins and nucleic acids offer excellent
ligands for binding to a metal ion. The pharmaceutical use of metal complexes therefore has
excellent potential. Designing ligands that will interact with free or protein-bound metal ions
are also a recent focus of medicinal inorganic research.
3.1 Molecular docking studies of farnesyltransferase
Docking studies predicted the interaction of ligands with protein and residues involved in this
complex. In such interaction studies, the most important requirement was the proper
orientation and conformation of ligand which fitted to the enzyme binding site appropriately
and formed protein-ligand complex. Therefore, optimal interactions and the best autodock
score were used as criteria to interpret the best conformation among the 30 conformations,
generated by AutoDock program. The docking results of Azacitidine, Gemcitabine,
Tipifarnib and Toremifene inhibitors with farnesyltransferase are shown in table 5.1. The
www.wjpr.net
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results show that Azacitidine, Gemcitabine, Tipifarnib and Toremifene inhibitors have low
binding, docking and internal energies with farnesyltransferase in presence of Zinc metal ion.
However, in the absence of Zn metal ion these energies are increasing. This shows that Zinc
plays a biological role in the binding of inhibitor at the catalytic site of farnesyltransferase
protein.
A close view of the binding interactions of farnesyltransferase with

Azacitidine,

Gemcitabine, Tipifarnib and Toremifene inhibitors were analysed through PyMol viewer
with and without Zinc metal ion are shown below in Figure 1(a-b) to 4(a-b) respectively.
Ligand is coloured in red (in stick drawing) where as amino acids involved in hydrogen
bonds color by atom. In docking complex between Farnesyltransferase and inhibitor
Azacitidine with Zinc, One H-bond is formed between amino acid TYR361 (O) and
Azacitidine (H) with bond length 2.15Å (fig. 1a). In case of without Zinc, One H-bond is
formed between amino acid TYR361 (O) and Azacitidine (H) with bond length 1.94Å and
5.90 Å (fig.1b).
In docking complex between Farnesyltransferase and inhibitor Gemcitabine with Zinc, three
H-bond is formed between amino acid TYR361 (O) and Gemcitabine (H) with bond length
3.11 Å, 2.71 Å, 6.07 Å, 5.14 Å and 2.19Å (fig. 2a). In case of without Zinc, four H-bond is
formed between amino acid TYR361 (O) and Gemcitabine (H) with bond length 5.50 Å, 6.68
Å, 1.99 Å and 6.85Å. (fig.2b).

In docking complex between Farnesyltransferase and inhibitor Tipifarnib with Zinc, One Hbond is formed between amino acid TYR361 (OH) and Tipifarnib (H) with bond length
3.07Å and 1.81 Å (fig. 3a). In case of without Zinc, two H-bond is formed between amino
acid TYR361 (OH) and Tipifarnib (H) with bond length 2.09Å and 2.90 Å (fig.3b).
In docking complex between Farnesyltransferase and inhibitor Toremifene with Zinc, No Hbond is formed between amino acid with Tipifarnib (fig. 4a). In case of without Zinc, One Hbond is formed between amino acid TYR361 (OH) and Toremifene (O) with bond length
2.93Å (fig.4b).
Role of zinc in Farnesyltransferase structure and function
Farnesyltransferase has two subunits: a 48kDa alpha subunit and a 46kDa beta subunit. Both
subunits are primarily composed of alpha helices. The α subunit is made of a double layer of
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paired alpha helices stacked in parallel, which wraps partly around the beta subunit like a
blanket. The alpha helices of the β subunit form a barrel. The active site is formed by the
center of the β subunit flanked by part of the subunit. Farnesyltransferase coordinates a zinc
cation on it β subunit at the lip of the active site.
3.2 Molecular docking studies of neuraminidase
The docking results of Oseltamivir and Zanamivir inhibitors with neuraminidase are shown in
table 5.2. The result shows that Oseltamivir and Zanamivir inhibitors have low binding,
docking and internal energies with neuraminidase in presence of calcium metal ion. However
in the absence of Ca metal ion these energies are increase. This shows that calcium play a
biological role in the binding of inhibitor at catalytic site of neuraminidase protein.
A close view of the binding interactions of neuraminidase with Oseltamivir and Zanamivir
inhibitors was analyzed through PyMol viewer with and without calcium metal ion are shown
below in Figure 5(a-b) to 6(a-b) respectively. Ligand is coloured in red (in stick drawing)
where as amino acids involved in hydrogen bonds color by atom.
In docking complex between Neuraminidase and inhibitor Oseltamivir with Calcium, Three
H-bond is formed between amino acid ASP151(O), GLU119(O), ARG 371(N) and
Oseltamivir (H) with bond length 2.82 Å, 2.09 Å, 1.66 Å, 2.79 Å, and 3.61 Å (fig. 5a). In
case of without Calcium, Two H-bond is formed between amino acid GLU119 (O), ARG371
(N) and Oseltamivir (O) with bond length 3.18 Å, 1.61 Å and 2.77Å (fig.5b).
In docking complex between Neuraminidase and inhibitor Zanamavir with Calcium, Four Hbond is formed between amino acid GLU277 (O), SER179 (O), TYR406 (O), ASP151 (O)
and Zanamavir (O) with bond length 2.10 Å, 1.81 Å, 2.03 Å , 3.76 Å,4.01 Å, 2.35Å. (fig.
6a). In case of without Calcium, Four H-bond is formed between amino acid GLU277 (O),
GLU276(O), TYR406(O), ASP151(O) and Zanamavir (H) with bond length 2.39 Å,6.22 Å,
4.07 Å , 3.73 Å (fig.6b).
Role of calcium in influenza virus Neuraminidase protein
In structures of NA determined previously, a calcium ion is observed to coordinate amino
acids near the substrate-binding site. In three of the NA monomers determined here this
calcium is absent, resulting in structural alterations near the substrate-binding site. These
changes affect the conformation of residues that participate in several key interactions
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between the enzyme and substrate and provide at a molecular level the basis of the structural
and functional role of calcium in substrate and inhibitor binding.
3.3 Molecular docking studies of Thioredoxin
The docking results of Granisetron and Nilutamide inhibitors with Thioredoxin are shown in
table 5.3. The result shows that Granisetron and Nilutamide inhibitors have low binding,
docking and internal energies with Thioredoxin in the presence of copper metal ions.
However, in the absence of Cu metal ion these energies are increasing. This shows that
copper plays a biological role in the binding of inhibitor at the catalytic site of thioredoxin
protein.
A close view of the binding interactions of neuraminidase with Granisetron and Nilutamide
inhibitors was analyzed through PyMol viewer with and without copper metal ion are shown
below in Figure 4.16 to 4.19 respectively. Ligand is coloured in red (in stick drawing) where
as amino acids involved in hydrogen bonds color by atom.
In docking complex between Thioredoxin and inhibitor Granisetron with Copper, no H-bond
is formed between the amino acid and Granisetron (fig. 7a). In case of without Copper, no Hbond is formed between the amino acid and Granisetron (fig. 7b).
In docking complex between Thioredoxin and inhibitor Granisetron with Copper, no H-bond
is formed between the amino acid and Granisetron (fig. 7a). In case of without Copper, no Hbond is formed between the amino acid and Granisetron (fig. 7b).
3.4 Biological relevance of Copper
Copper is an essential micronutrient required by all life forms. Cu is a transition metal and
hence involved in a variety of biological processes viz., embryonicdevelopment,
mitochondrial respiration, regulation of hemoglobin levels as well as hepatocyte and neuronal
functions. Being a transition metal, Cu gets biologically converted between different redox
states, namely oxidized Cu (II) and reduced Cu (I). This unique attribute has made Cu metal
to get manifested as an important catalytic co-factor for a variety of metabolic reactions in
biological systems.
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Table 1: List of experimentally known inhibitors.
Sl.
No.
1
2
3
4
5
6
7
8

Inhibitor
Name
Azacitidine
Gemcitabine
Tipifarnib
Toremifene
Oseltamivir
Zanamivir
Granisetron
Nilutamide

CID
No.
9444
60750
159324
3005573
65028
60855
5284566
4493

MWT
(g/mol)
244.20468
263.198146
489.39578
405.95962
312.40452
332.3098
312.40936
317.22071

Molecular
X Log P
formula
C8H12N4O5
-2.2
C9H11F2N3O4
-1.5
C27H22Cl2N4O
4.1
C26H28ClNO
7.2
C16H28N2O4
1.1
C12H20N4O7
-3.2
C18H24N4O
2.8
C12H10F3N3O4
2

HBD

HBA

4
3
1
0
2
7
1
1

5
6
3
2
5
8
3
7

Table 2: The docking results of known inhibitors with farnesyltransferase.
Sl.
No
1
2
3
4
5
6
7
8

Inhibitor
Name
Azacitidin
Azacitidin
Gemcitabie
Gemcitabie
Tipifarnib
Tipifarnib
Toremifen
Toremifene

Metal
ion
Zn
absent
Zn
absent
Zn
absent
Zn
absent

Binding
Energy
(Kcal/mo
l)
-5.66
-11.37
-5.18
-5.45
-8.06
-12.84
-6.91
-10.25

Docking
Energy
(Kcal/mol
)
-6.2
-12.0
-5.43
-5.64
-5.75
-10.71
-9.74
-13.23

Intermol
Energy
(Kcal/mol)
-6.28
-11.99
-5.8
-6.07
-9.3
-14.09
-9.71
-13.05

Torsiona
l Energy
(Kcal/mo
l)
0.62
0.62
0.62
0.62
1.25
1.25
2.8
2.8

Internal
Energy
(Kcal/mol)
0.08
-0.01
0.37
0.43
3.56
3.38
-0.03
-0.18

Table 3: The docking results of known inhibitors with Neuraminidase.
Sl.
No
1
2
3
4

Inhibitor
Name
Oseltamivir
Oseltamivir
Zanamivir
Zanamivir

Metal
ion
Ca
absent
Ca
absent

Binding
Docking
Energy
Energy
(Kcal/mo (Kcal/mol
l)
)
-7.16
-10.38
-15.01
-18.19
-6.63
-8.48
-7.51
-10.0

Intermol
Energy
(Kcal/mol)
-9.96
-17.81
-8.81
-9.69

Torsiona
l Energy
(Kcal/mo
l)
2.8
2.8
2.18
2.18

Internal
Energy
(Kcal/mol)
-0.43
-0.38
0.34
-0.31

Table 4: The docking results of known inhibitors with Thioredoxin.
Sl.
No
1
2
3
4

Inhibitor
Name
Granisetro
nGranisetro
n
Nilutamide

Meta
l ion

Cu
absen
t
Cu
Nilutamide absen
t

www.wjpr.net

Binding
Docking
Energy
Energy
(Kcal/mo (Kcal/mol
l)
)
-5.32
-6.55

Intermol
Energy
(Kcal/mol)
-6.26

Torsiona
l Energy
(Kcal/mo
l)
0.93

Internal
Energy
(Kcal/mol)
-0.29

-5.27
-3.15

-6.6
-4.01

-6.2
-4.08

0.93
0.93

-0.4
0.08

-3.8

-4.64

-4.74

0.93

0.1
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(a)

(b)

Figure 1(a-b): The docking structure of complex between Farnesyltransferase and
inhibitor Azacitidine (a) with Zinc and (b) without Zinc. Inhibitor Azacitidine is show
in sticks representation and is colored with red using PyMol viewer. Amino acid
residues are represented as lines. Hydrogen bond is represented by yellow dotted line.
(a)

(b)

Figure 2(a-b): The docking structure of complex between Farnesyltransferase and
inhibitor Gemcitabine (a) with Zinc and (b) without Zinc. Inhibitor Azacitidine is show
in sticks representation and is colored with red using PyMol viewer. Amino acid
residues are represented as lines. Hydrogen bond is represented by yellow dotted line.
(a)

(b)

Figure 3(a-b): The docking structure of complex between Farnesyltransferase and
inhibitor Tipifarnib (a) with Zinc and (b) without Zinc. Inhibitor Azacitidine is show
in sticks representation and is colored with red using PyMol viewer. Amino acid
residues are represented as lines. Hydrogen bond is represented by yellow dotted line.
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(b)

Figure 4(a-b): The docking structure of complex between Farnesyltransferase and
inhibitor Toremifene (a) with Zinc and (b) without Zinc. Inhibitor Azacitidine is show
in sticks representation and is colored with red using PyMol viewer. Amino acid
residues are represented as lines. Hydrogen bond is represented by yellow dotted line.
(a)

(b)

Figure 5(a-b): The docking structure of complex between neuraminidase and inhibitor
Oseltamivir (a) with Calcium and (b) without Calcium. Inhibitor Oseltamivir is show
in sticks representation and is colored with red using PyMol viewer. Amino acid
residues are represented as lines. Hydrogen bond is represented by yellow dotted line.
(a)

(b)

Figure 6(a-b): The docking structure of complex between Neuraminidase and
inhibitor Zanamavir (a) with Zinc and (b) without Zinc. Inhibitor Azacitidine is show
in sticks representation and is colored with red using PyMol viewer. Amino acid
residues are represented as lines. Hydrogen bond is represented by yellow dotted line.
www.wjpr.net
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(b)

Figure 7(a-b): The docking structure of complex between Thioredoxin and inhibitor
Granisetron (a) with Copper and (b) without Copper. Inhibitor Granisetron is show in
sticks representation and is colored with red using PyMol viewer. Amino acid residues
are represented as lines. Hydrogen bond is represented by yellow dotted line.
(a)

(b)

Figure 8(a-b): The docking structure of complex between Thioredoxin and inhibitor
Nilutamide (a) with Copper and (b) without Copper. Inhibitor Nilutamide is show in
sticks representation and is colored with red using PyMol viewer. Amino acid
residues are represented as lines. Hydrogen bond is represented by yellow dotted line.
4. CONCLUSION
Metal play a critical role in the function of Farnesyltransferase, Neuraminidase and
Thioredoxin proteins. Metals can have purely stabilized roles, or may be central to protein
activity, perhaps involved in enzyme activity. Our results suggested that the environment of
metals in proteins is quite different from the aqueous environment and this may confer
unusual properties of the metal such that it may be better suited to a particular role in
structural stability or catalysis.
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